Neuropace Inc (NPCE) Stock Price, Quote & News

Company Profile

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for...

Industry: Medical Devices

Sector: Healthcare

Phone: 650 237 2700

Website: www.neuropace.com

Address:

455 North Bernardo Avenue, Mountain View, United States

StocktwitsEarnings Mar. 3 at 10:05 PM

$NPCE Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.08 up 55.56% YoY • Reported revenue of $26.59M up 23.86% YoY • NeuroPace expects its cash, cash equivalents, and short-term investments will fund operations for at least 12 months from December 31, 2025, and its trailing 12-month RNS System revenue of $81.7 million exceeded the $71.0 million minimum covenant.

0 · Reply

d_risk Mar. 3 at 10:03 PM

$NPCE - Neuropace Inc - 10K - Updated Risk Factors NPCE’s risk profile now flags QMSR manufacturing compliance, weaker NAUTILUS topline efficacy, heightened exposure to shifting tariffs and trade tensions, major U.S. health policy and Medicaid cuts (OBBBA, Great Healthcare Plan), stricter global data/AI rules, new DOJ data-transfer limits, loss of the DIXI distribution upside, tighter MidCap debt covenants, and vulnerability to FDA/SEC shutdowns. #MedicalDevices #RegulatoryCompliance #TradeTariffs #HealthcarePolicy #DataPrivacy 🟢 Added 🟠 Removed https://d-risk.ai/NPCE/10-K/2026-03-03

0 · Reply

BillionerOfKing Feb. 23 at 11:27 AM

$NPCE Current Stock Price: $14.35 Contracts to trade: $15.0 NPCE Mar 20 2026 Call Entry: $2.46 Exit: $3.25 ROI: 32% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Bogwood Feb. 22 at 10:50 PM

$NPCE $STAA Glad to see Patrick got quickly back on his feet after last year's implosion. I always felt like he and Tom were dealt short hands of the stick, just unlucky timing. What a consequential beard, though! 😂

0 · Reply

OfficialStocktwitsUser Feb. 21 at 1:34 PM

$NPCE RSI: 42.59, MACD: -0.4092 Vol: 0.68, MA20: 15.38, MA50: 15.95 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

VolatilityControl Feb. 18 at 4:40 PM

$NPCE NeuroPace develops implantable epilepsy devices. Adoption depends on physician acceptance and reimbursement. Growth is steady but niche.

0 · Reply

RebeccaDory286 Feb. 11 at 3:48 PM

$NPCE NeuroPace; medical device (responsive neurostimulation for epilepsy); commercial-stage; adoption is gradual, reimbursement path.

0 · Reply

topstockalerts Feb. 6 at 2:26 PM

$NPCE look who’s waking up..

0 · Reply

EquityEnforcer Feb. 4 at 4:07 PM

$NPCE is a medical device or healthcare services company; its performance would be tied to factors like patient volumes, reimbursement rates, or product adoption.

0 · Reply

IncognitoBull Jan. 30 at 1:24 PM

$NPCE if you believe in NPCE, you should also check out $NMTC competing tech, we are just getting to commercialization, but, our tech is targeting additional uses, brain, pain, and drug delivery. Ground floor prices vs a weighted top.

0 · Reply

NeuroPace to Present at the Leerink Global Healthcare Conference

Mar 3, 2026, 9:02 PM EST - 16 days ago

NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript

Mar 3, 2026, 4:05 PM EST - 16 days ago

NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

Feb 20, 2026, 4:30 PM EST - 27 days ago

NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026

Jan 14, 2026, 7:46 PM EST - 2 months ago

NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 7:30 AM EST - 2 months ago

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

Dec 31, 2025, 9:00 AM EST - 2 months ago

NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 8:00 AM EST - 3 months ago

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

Dec 8, 2025, 8:00 AM EST - 3 months ago

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

Dec 2, 2025, 8:01 AM EST - 3 months ago

NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting

Nov 24, 2025, 8:00 AM EST - 4 months ago

NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

Nov 4, 2025, 11:06 PM EST - 4 months ago

NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:05 PM EST - 4 months ago

NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Oct 22, 2025, 8:00 AM EDT - 5 months ago

NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025

Aug 28, 2025, 8:00 AM EDT - 7 months ago

NeuroPace to Participate in Upcoming Healthcare Conferences

Aug 12, 2025, 9:50 PM EDT - 7 months ago

NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 7 months ago

NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Aug 1, 2025, 7:30 AM EDT - 8 months ago

NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases

Jun 24, 2025, 4:05 PM EDT - 9 months ago

NeuroPace Announces Strategic CFO Transition

Jun 24, 2025, 3:42 AM EDT - 9 months ago

NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm

Jun 13, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect

Jun 12, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Shareholders to Reach Out

Jun 11, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Shareholders to Learn More About the Investigation

Jun 10, 2025, 10:00 AM EDT - 10 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 9, 2025, 10:00 AM EDT - 10 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Investors to Connect

Jun 6, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Stockholders to Inquire about Securities Investigation

Jun 5, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Investors to Learn More About the Investigation

Jun 4, 2025, 4:09 PM EDT - 10 months ago

NeuroPace Secures Up to $75 Million in Debt Financing

Jun 3, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Stockholders to Reach Out

Jun 2, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Stockholders to Connect

Jun 1, 2025, 10:00 AM EDT - 10 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Stockholders to Learn More About the Investigation

May 29, 2025, 12:45 PM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Investors to Inquire about Securities Investigation

May 27, 2025, 12:48 PM EDT - 10 months ago

Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?

May 27, 2025, 8:00 AM EDT - 10 months ago

NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

May 13, 2025, 10:33 PM EDT - 11 months ago

NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 11 months ago

NeuroPace Reports First Quarter 2025 Financial Results

StocktwitsEarnings Mar. 3 at 10:05 PM

0 · Reply

d_risk Mar. 3 at 10:03 PM

0 · Reply

BillionerOfKing Feb. 23 at 11:27 AM

0 · Reply

Bogwood Feb. 22 at 10:50 PM

0 · Reply

OfficialStocktwitsUser Feb. 21 at 1:34 PM

0 · Reply

VolatilityControl Feb. 18 at 4:40 PM

$NPCE NeuroPace develops implantable epilepsy devices. Adoption depends on physician acceptance and reimbursement. Growth is steady but niche.

0 · Reply

RebeccaDory286 Feb. 11 at 3:48 PM

$NPCE NeuroPace; medical device (responsive neurostimulation for epilepsy); commercial-stage; adoption is gradual, reimbursement path.

0 · Reply

topstockalerts Feb. 6 at 2:26 PM

$NPCE look who’s waking up..

0 · Reply

EquityEnforcer Feb. 4 at 4:07 PM

$NPCE is a medical device or healthcare services company; its performance would be tied to factors like patient volumes, reimbursement rates, or product adoption.

0 · Reply

IncognitoBull Jan. 30 at 1:24 PM

0 · Reply

OfficialStocktwitsUser Jan. 26 at 7:42 PM

$NPCE RSI: 54.51, MACD: 0.3089 Vol: 0.62, MA20: 16.40, MA50: 15.88 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Grubnednarb Jan. 8 at 3:47 AM

$NPCE

0 · Reply

Scoops1212 Jan. 7 at 6:05 PM

$NPCE This is about as frustrating of a stock that you can own. I’ve crunched all the numbers and this should be at 40+ right now there is something holding this price down, and it’s not visible in the numbers. Check their quarterly, and some big investors holding their position. When will this launch, as it’s long overdue?

0 · Reply

OfficialStocktwitsUser Dec. 29 at 11:20 AM

$NPCE RSI: 44.41, MACD: 0.5827 Vol: 0.38, MA20: 16.25, MA50: 13.84 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

erevnon Dec. 16 at 3:31 PM

UBS maintains NeuroPace $NPCE at Buy and raises the price target from $18 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Dec. 16 at 2:27 PM

UBS has adjusted their stance on NeuroPace ( $NPCE ), setting the rating to Buy with a target price of 18 → 22.

0 · Reply

JarvisFlow Dec. 10 at 4:00 PM

JP Morgan has updated their rating for NeuroPace ( $NPCE ) to Overweight with a price target of 20.

0 · Reply

SuperGreenToday Dec. 9 at 9:37 PM

$NPCE Share Price: $16.26 Contract Selected: May 15, 2026 $17.5 Calls Buy Zone: $0.73 – $0.90 Target Zone: $1.36 – $1.66 Potential Upside: 76% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

stockwitsuser2449 Dec. 1 at 12:35 PM

$NPCE

0 · Reply

stockwitsuser2449 Nov. 20 at 7:07 PM

$NPCE large drop here

1 · Reply

HypnoTrader Nov. 19 at 6:48 PM

$NPCE no way to confirm anything an anonymous account is telling you, but the chart seems to agree....

1 · Reply

HypnoTrader Nov. 19 at 6:46 PM

$NPCE

0 · Reply

Market Cap	456.52M
Revenue (ttm)	99.99M
Net Income (ttm)	-21.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-21.47%
Debt to Equity Ratio	3.09

Volume	198,300
Avg Vol	218,176
Day's Range	N/A - N/A
Shares Out	33.67M
Stochastic %K	7%
Beta	1.86
Analysts	Strong Sell
Price Target	$20.00